✦ LIBER ✦

819 Can inhibition of epidermal growth factor receptor (EGFR) with gefitinib (‘iressa’, ZD1839) improve response to ionising radiation in bladder cancer cell lines?

✍ Scribed by A.J. Colquhoun; S.P. Wozniak; E.M. Tulchinsky; M. Kriajevska; J.K. Mellon

Book ID: 118646020
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 214 KB
Volume: 3
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(04)90811-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib (‘Iressa’, ZD1839) inhibits th

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2

✍ Nutt, J E; Lazarowicz, H P; Mellon, J K; Lunec, J 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 147 KB

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro

213 Epidermal growth factor receptor (EG

213 Epidermal growth factor receptor (EGFR) blockade with tarceva (erlotinib) potentiates the antitimour effect of ionising radiation in bladder cancer cell lines

✍ A.J. Colquhoun; J.K. Mellon 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 200 KB